Immuron Limited (IMRN)

Market Cap	11.64M
Revenue (ttm)	3.27M
Net Income (ttm)	-4.63M
Shares Out	228.00M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,221
Open	2.034
Previous Close	2.020
Day's Range	1.900 - 2.034
52-Week Range	1.650 - 5.960
Beta	1.16
Analysts	Strong Buy
Price Target	5.00 (+163.16%)
Earnings Date	Mar 3, 2025

About IMRN

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive func...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: IMRN
• Website: https://www.immuron.com.au

Financial Performance

In 2024, Immuron's revenue was 4.90 million, an increase of 171.67% compared to the previous year's 1.80 million. Losses were -6.94 million, 83.2% more than in 2023.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for IMRN stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(163.16% upside)

Analyst Consensus: Strong Buy